28.06
+0.22
(0.79%)
May 23 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 26.57 - 28.12 |
| 52 week | 9.78 - 29.00 |
| Open | 27.46 |
| Vol / Avg. | 0.00/433,331.00 |
| Mkt cap | 1.74B |
| P/E | - |
| Div/yield | - |
| EPS | -1.98 |
| Shares | 62.17M |
| Beta | 1.27 |
| Inst. own | 77% |
Events
Aug 5, 2013
Q2 2013 Alnylam Pharmaceuticals Earnings Release
Jun 6, 2013
Alnylam Pharmaceuticals Annual Shareholder Meeting
- 9:00AM EDT -
May 29, 2013
Alnylam Pharmaceuticals at 38th Annual dbAccess Health Care Conference
- 2:50PM EDT -
May 22, 2013
Alnylam Pharmaceuticals at UBS Global Healthcare Conference -
May 16, 2013
Alnylam Pharmaceuticals at Bank of America Merrill Lynch Health Care Conference -
May 6, 2013
Q1 2013 Alnylam Pharmaceuticals Earnings Conference Call -
Apr 30, 2013
Alnylam Pharmaceuticals at Needham Healthcare Conference -
Apr 29, 2013
Q1 2013 Alnylam Pharmaceuticals Earnings Release
Mar 12, 2013
Alnylam Pharmaceuticals at Barclays Healthcare Conference -
Mar 5, 2013
Alnylam Pharmaceuticals at Cowen Health Care Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -48.35% | -158.88% |
| Operating margin | -52.59% | -194.01% |
| EBITD margin | - | -77.50% |
| Return on average assets | -9.52% | -37.23% |
| Return on average equity | -16.23% | -84.12% |
| Employees | 129 | - |
| Carbon Disclosure Rating | - | - |
Address
3rd Floor, 300 Third Street
CAMBRIDGE, MA 02142
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)
CAMBRIDGE, MA 02142
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Alnylam Pharmaceuticals, Inc. (Alnylam) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). Its Alnylam 5x15, is focused on the development and commercialization of novel RNAi therapeutics for the treatment of genetically defined diseases. Its core programs in clinical or pre-clinical development are: ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR); ALN-APC for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN for the treatment of refractory anemia, and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The Company has three partner-based programs in clinical or pre-clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV), infection, ALN-VSP for the treatment of liver cancers and ALN-HTT for the treatment of Huntington�s disease (HD).
Officers and directors
| John K. Clarke | Independent Chairman of the Board | |
| Barry E. Greene | President, Chief Operating Officer | |
| John M. Maraganore Ph.D. | Chief Executive Officer, Director | |
| Akshay K. Vaishnaw Ph.D,M.D. | Executive Vice President, Chief Medical Officer | |
| Laurence E. Reid Ph.D. | Senior Vice President, Chief Business Officer | |
| Michael P. Mason | Vice President - Finance, Treasurer | |
| Philip A. Sharp Ph.D. | Director | |
| Dennis A. Ausiello M.D. | Independent Director | |
| Victor J. Dzau M.D. | Independent Director | |
| Marsha H. Fanucci | Independent Director |
